The American Association for Cancer Research (AACR) annual meeting is one of the largest gatherings of cancer researchers and oncologists in the world. The meeting is held 16-20 April in New Orleans. Biovica is attending the meeting to present a poster with new DiviTum™ results to demonstrate its use as a marker of efficacy for cell cycle regulating drugs and the ability to provide unique data for the impact on cell growth rate in a preclinical setting. Biovica aims to expand the collaboration and research network and to share the latest insights from on going clinical trials.


“At AACR we look forward to meet our research partners and to expand our collaborations with oncologists and pharmaceutical companies. The DiviTum™ data presented at the meeting demonstrates the potential of DiviTum™ to provide important information as a tool to evaluate efficacy of cell cycle regulating drugs in early development. Our ambition is to provide our partners access to the DiviTum™ technology to predict and evaluate drug efficacy for new cancer drugs so that patients can get the best possible treatment.” says Mattias Bergqvist, VP Marketing & Clinical Studies at Biovica.


We look forward to discuss the latest results with DiviTum as a tool in preclinical & clinical development. If you wish to meet us at the AACR meeting please do not hesitate to contact us at

Read more about AACR